• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Public Health

Vaporized nicotine products may be effective for smoking cessation among people with social disadvantage

byAdrian WongandThomas Su
July 14, 2025
in Public Health
Reading Time: 3 mins read
Vaping to quit smoking collage: a woman in a work jacket above a row of ever-shorter unlit cigarettes ending in a vape
Share on FacebookShare on TwitterShare on LinkedIn

1.  In this randomized controlled trial, vaporized nicotine products were associated with higher rates of smoking abstinence compared with nicotine gum and lozenges among people with low socioeconomic status.

2. The group which received vaporized nicotine products reported fewer adverse events and higher treatment adherence.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Despite positive trends in smoking cessation in higher-income countries, smoking rates remain high among socioeconomically disadvantaged groups. Studies have suggested that vaporized nicotine products (VNPs) may lead to higher rates of smoking cessation compared with nicotine replacement therapy (NRT). This study aimed to evaluate the relative effectiveness of VNPs and NRT on smoking cessation among low socioeconomic status (SES) groups. After half a year, more than one-quarter of VNP users achieved verified continuous abstinence compared with less than one-tenth of NRT users. Subgroup analyses by age, sex, nicotine dependence, and mental illness showed greater effectiveness of VNP compared to NRT in achieving smoking cessation. Self-reported adverse effects were lower in the VNP group compared with the NRT group, but there was no significant difference in the occurrence of serious adverse effects. More NRT users stopped adhering to treatment by the second check-in call compared with VNP users; the most common reasons for stopping NRT were related to distaste for the treatment and side-effects, while the most common reasons for stopping VNP were unrelated medical conditions and life stressors. At the final follow-up, the majority of VNP users continued to use their allocated treatment compared with less than one-third of NRT users. The generalizability of this study was limited by a lack of blinding, potentially different perceptions of VNP versus NRT, and potential underestimation of continued use. Nevertheless, this study suggested that VNP may be an effective choice for smoking cessation among socially disadvantaged groups.

Click to read this study in AIM

Relevant Reading: Electronic cigarettes for smoking cessation

RELATED REPORTS

Psilocybin in combination with cognitive behavioural therapy may improve smoking abstinence compared to nicotine patches

Baseline cannabis use may not be associated with abstinence from vaping

In-Depth [randomized controlled trial]: This study aimed to compare the effectiveness of VNPs and NRT in achieving smoking cessation among low SES individuals. A total of 1045 participants were randomly assigned to receive VNPs or NRT in a 1:1 ratio. The primary outcome was continuous smoking abstinence for 6 months assessed at 7-month follow-up; continuous smoking abstinence was defined as self-report of having smoked ≤5 tobacco cigarettes over a 6-month period and verified with a CO level of ≤5 ppm. The study population had a median age of 50 years, was 67% female, and smoked a median of 20 cigarettes a day. Among the participants, 82.9% completed the 7-month follow-up. Continuous abstinence after 6 months was achieved in 28.4% of VNP participants and 9.6% of NRT participants, yielding an estimated risk difference of 18.7% (95% credible interval [CrI], 14.1% to 23.3%). Quit rates were similar between participants with and without recent diagnosis or treatment of mental illness in both treatment groups (26% vs. 30% for VNP and 9% vs. 10% for NRT, respectively). Self-reported abstinence outcomes at all time points showed that VNP was more effective than NRT.  Users of VNPs also reported fewer adverse events (355 events reported by 237 participants) compared with NRT users (442 events reported by 278 participants); the incidence rate ratio was 0.75 (95% confidence interval, 0.65 to 0.88). An estimated 11.5% fewer participants experienced adverse events in the VNP group (posterior risk difference, -11.5% [95% CrI, -17.6% to -5.3%]). The most frequent adverse events were COVID-19, cough, headache, and nausea; cough and headache occurred more frequently among VNP users and nausea more frequently among NRT users. At the 7-month follow-up, 253 (56.3%) VNP users and 129 (30.9%) NRT users reported continued treatment use. Overall, this study suggested that VNP may be more effective than NRT in aiding smoking cessation in a low SES population.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: abstinencecigarette smokingnicotine replacement therapy (NRT)smoking cessationsocioeconomic statusvaping
Previous Post

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

Next Post

Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes

RelatedReports

Smoking collage: an unlit cigarette, a spent match and a closed metal lighter lying on torn blue paper below a teal ribbon
Chronic Disease

Psilocybin in combination with cognitive behavioural therapy may improve smoking abstinence compared to nicotine patches

March 16, 2026
Cannabis and alcohol use collage: an engraved cannabis leaf, an empty tumbler glass and a car steering wheel by a road ribbon
Chronic Disease

Baseline cannabis use may not be associated with abstinence from vaping

January 13, 2026
Bisphosphonate use and risk of atypical femur fractures
Orthopedic Surgery

Neighbourhood socioeconomic status may be associated with days spent at home following hip fracture in older adults

January 12, 2026
Letrozole (Femara) boosts fertility of women with Polycystic Ovarian Syndrome
Weekly Rewinds

2 Minute Medicine Rewind December 15, 2025

December 15, 2025
Next Post
Digestive health collage: an engraved digestive tract from esophagus to colon, a knitted hot-water bottle, ginger and mint

Glucagon-like peptide-1 receptor agonists may increase risk of reflux in patients with type 2 diabetes

Violence prevention collage: a white dove carrying a green sprig over a row of young trees, and a rolled white bandage

St. Louis hospital-based violence intervention program did not significantly affect reinjury outcomes

#VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk

#VisualAbstract: Obicetrapib Reduced LDL Cholesterol in Patients at High Cardiovascular Risk

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence-generated pre-visit summaries improved communication outcomes in neurosurgical consultations
  • Midline catheters may reduce catheter-related bloodstream infections compared with peripherally inserted central catheters in intensive care unit patients
  • AI scribe use associated with reduced documentation time but longer clinical notes
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.